Hilde Lavreysen

This inventor holds 6 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignee: Janssen Pharmaceutica Nv. Active years: 2009-2024.

USPTO Granted Patents = 6 (Patent Applications = 3)

% Patents Active = 83.3

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 6.5

ph-index = 1

Forward Citations = 8(Granted Patents)

Company Filing History:

6 out of 2,099

Janssen Pharmaceutica Nv

patents

Years Active: 2009-2024

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12048696 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2024-07-30),

2. 11369606 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2022-06-28),

3. 11103506 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2021-08-31),

4. 10537573 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2020-01-21),

5. 9708315 - 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors (2017-07-18),

6. 7517517 - Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands (2009-04-14),

Title: The Innovative Mind of Hilde Lavreysen

Introduction

Hilde Lavreysen is a notable inventor based in Lommel, Belgium, who has made significant contributions to the field of pharmaceuticals. With a portfolio of six patents, her work focuses on advancements in metabotropic glutamatergic receptor subtype 2 (mGluR2) and its therapeutic potential.

Latest Patents

Among her latest patents, Lavreysen has developed combinations comprising positive allosteric modulators (PAMs) or orthosteric agonists of metabotropic glutamatergic receptor subtype 2. These innovations aim to enhance the effectiveness of pharmaceuticals targeting mGluR2 along with synaptic vesicle protein 2A (SV2A) ligands. The invention showcases a promising approach to improve treatment outcomes in various neurological conditions.

Career Highlights

Hilde Lavreysen has established her professional career at Janssen Pharmaceutica NV, a company recognized for its research and development in health solutions. Her role within this prominent organization emphasizes her commitment to tackling complex medical challenges through innovative inventions in the pharmaceutical industry.

Collaborations

Throughout her work, Lavreysen has collaborated with impressive colleagues in her field, including José Maria Cid-Núñez and Andrés Avelino Trabanco-Suárez. These partnerships reflect the collaborative spirit of innovation in the pharmaceutical research community and contribute to the successful development of her patents.

Conclusion

Hilde Lavreysen's inventive contributions highlight the importance of research in the pharmaceutical sector. Her work not only advances scientific knowledge but also has the potential to offer new treatment avenues for individuals affected by neurological disorders. As she continues to innovate, her influence on the field will undoubtedly grow, inspiring future generations of inventors.